Brokerages forecast that TherapeuticsMD, Inc. (NASDAQ:TXMD) will post $4.69 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for TherapeuticsMD’s earnings, with estimates ranging from $4.00 million to $5.50 million. TherapeuticsMD posted sales of $4.49 million during the same quarter last year, which suggests a positive year over year growth rate of 4.5%. The company is expected to report its next earnings report on Thursday, February 22nd.
On average, analysts expect that TherapeuticsMD will report full-year sales of $4.69 million for the current financial year, with estimates ranging from $16.70 million to $18.15 million. For the next fiscal year, analysts expect that the firm will report sales of $36.78 million per share, with estimates ranging from $18.76 million to $74.22 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for TherapeuticsMD.
TXMD has been the topic of several recent research reports. BidaskClub cut shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday, October 13th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, October 16th. Cowen reaffirmed an “outperform” rating and set a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a report on Wednesday, November 29th. Finally, Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.50.
In other news, Director Tommy G. Thompson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 23.92% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Candriam Luxembourg S.C.A. grew its stake in shares of TherapeuticsMD by 10.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after buying an additional 50,000 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of TherapeuticsMD by 26.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after buying an additional 30,030 shares during the last quarter. Swiss National Bank grew its stake in shares of TherapeuticsMD by 12.3% during the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after buying an additional 31,800 shares during the last quarter. Finally, State Street Corp grew its stake in shares of TherapeuticsMD by 14.9% during the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after buying an additional 583,094 shares during the last quarter. 73.86% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “TherapeuticsMD, Inc. (TXMD) Expected to Announce Quarterly Sales of $4.69 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/07/therapeuticsmd-inc-txmd-expected-to-announce-quarterly-sales-of-4-69-million-4.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.